ReviewFrontiers in pediatrics2026
Gut microbiota and pediatric metabolic dysfunction-associated steatotic liver disease: clinical evidence and therapeutic implications.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as Non-alcoholic fatty liver disease (NAFLD), is among the most common chronic liver conditions globally. The incidence of MASLD has been rising, primarily due to lifestyle changes, excessive calorie intake, and other metabolic conditions like obesity and Type 2 diabetes mellitus in both adults and children. An inclusive understanding of risk factors of childhood MASLD is still unknown. Based on the limited case studies published, familial clustering is prominent in MASLD suggesting role of genetic factors. Moreover, children with MASLD are at higher risk of obesity, diabetes and hypertension. Studies associating the colonic microbiome with MASLD have been limited and complicated by inconsistencies in study design and approach but mostly indicate a role in the pediatric population. The present review provides a comprehensive understanding of the most recent clinical studies (2013-2026) on the role of gut microbiome in the development of pediatric MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.